Literature DB >> 1607075

Coordinate regulation of amylin and insulin expression in response to hypoglycemia and fasting.

T Alam1, L Chen, A Ogawa, J D Leffert, R H Unger, K L Luskey.   

Abstract

Amylin is a 37-amino acid peptide synthesized in the pancreatic beta-cell and cosecreted with insulin. In situ hybridization of nondiabetic rat pancreas shows that insulin and amylin RNA are both localized within the islet of Langerhans in a similar distribution. After 12 days of insulin-induced hypoglycemia (mean blood glucose 3.0 +/- 0.4 mM [54 +/- 8 mg/dl]), both insulin and amylin RNA fell greater than 95%. However, maintenance of euglycemia by simultaneous infusion of glucose with insulin did not suppress insulin or amylin RNA. Fasting suppressed amylin and insulin secretion from the isolated, perfused pancreas 70 and 58%, respectively, and with refeeding, secretion rates recovered to fed levels. Despite these changes in the rates of secretion, the relative ratio of amylin to insulin was not significantly different in fed, fasted, or refed rats. The molar ratio of insulin to amylin was estimated to be 100:2.3-2.6. Both insulin and amylin RNA was suppressed approximately 50% in response to fasting. Thus, although the absolute amounts of insulin and amylin change substantially under the conditions tested, the relative amounts of these peptides do not change.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607075     DOI: 10.2337/diab.41.4.508

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  Amylin receptor signaling in the nucleus accumbens negatively modulates μ-opioid-driven feeding.

Authors:  Sarah K Baisley; Brian A Baldo
Journal:  Neuropsychopharmacology       Date:  2014-06-24       Impact factor: 7.853

2.  Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway.

Authors:  S E Kahn; C B Verchere; D A D'Alessio; D L Cook; W Y Fujimoto
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

3.  Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats.

Authors:  H Mulder; B Ahrén; F Sundler
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

Review 4.  Mediators of Amylin Action in Metabolic Control.

Authors:  Christina N Boyle; Yi Zheng; Thomas A Lutz
Journal:  J Clin Med       Date:  2022-04-15       Impact factor: 4.964

5.  Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis.

Authors:  N Blume; J Skouv; L I Larsson; J J Holst; O D Madsen
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia.

Authors:  J W Höppener; J S Verbeek; E J de Koning; C Oosterwijk; K L van Hulst; H J Visser-Vernooy; F M Hofhuis; S van Gaalen; M J Berends; W H Hackeng
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

7.  Differential expression of rat pancreatic islet beta-cell glucose transporter (GLUT 2), proinsulin and islet amyloid polypeptide genes after prolonged fasting, insulin-induced hypoglycaemia and dexamethasone treatment.

Authors:  L Koranyi; R Bourey; J Turk; M Mueckler; M A Permutt
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

8.  Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

Authors:  Wei Qiao Qiu; Haihao Zhu
Journal:  Front Aging Neurosci       Date:  2014-07-29       Impact factor: 5.750

9.  Label-free detection of insulin and glucagon within human islets of Langerhans using Raman spectroscopy.

Authors:  Janneke Hilderink; Cees Otto; Cees Slump; Aufried Lenferink; Marten Engelse; Clemens van Blitterswijk; Eelco de Koning; Marcel Karperien; Aart van Apeldoorn
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.